Abbreviations used : AVP, vasopressin ; GLP-1, glucagon-like peptide-1 ; OX, oxytocin ; PVN, paraventricular nucleus ; SON, supraoptic nucleus.
Coexpression of Glucagon-Like Peptide-1 (GLP-1) Receptor, Vasopressin, and Oxytocin mRNAs in Neurons of the Rat Hypothalamic Supraoptic and Paraventricular Nuclei
Effect of GLP-1 (7-36) Amide on Vasopressin and Oxytocin Release
Article first published online: 18 JAN 2002
Journal of Neurochemistry
Volume 72, Issue 1, pages 10–16, January 1999
How to Cite
Zueco, J. A., Esquifino, A. I., Chowen, J. A., Alvarez, E., Castrillón, P. O. and Blázquez, E. (1999), Coexpression of Glucagon-Like Peptide-1 (GLP-1) Receptor, Vasopressin, and Oxytocin mRNAs in Neurons of the Rat Hypothalamic Supraoptic and Paraventricular Nuclei. Journal of Neurochemistry, 72: 10–16. doi: 10.1046/j.1471-4159.1999.0720010.x
- Issue published online: 18 JAN 2002
- Article first published online: 18 JAN 2002
- Glucagon-like peptide-1 receptor;
Abstract : This study was designed to gain better insight into the relationship between glucagon-like peptide-1 (GLP-1) (7-36) amide and vasopressin (AVP) and oxytocin (OX). In situ hybridization histochemistry revealed colocalization of the mRNAs for GLP-1 receptor, AVP, and OX in neurons of the hypothalamic supraoptic and paraventricular nuclei. To determine whether GLP-1(7-36)amide alters AVP and/or OX release, both in vivo and in vitro experimental study designs were used. In vivo, intravenous administration of 1 μg of GLP-1(7-36)amide into the jugular vein significantly decreased plasma AVP and OX concentrations. In vitro incubation of the neurohypophysis with either 0.1 or 1 μg of GLP-1(7-36)amide did not modify the release of AVP. However, addition of 1 μg of GLP-1(7-36)amide to the incubation medium increased slightly the secretion of OX. The coexpression of GLP-1 receptor and AVP mRNAs in hypothalamic supraoptic and paraventricular nuclei gives further support to the already reported central effects of GLP-1(7-36)amide on AVP. Our findings also suggest a dual secretory response of AVP and OX to the effect of GLP-1(7-36)amide, which most likely is related to the amount and/or the route of peptide administration.